MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Alnylam Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

267.08 4.76

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

252.55

Максимум

267.08

Ключови измерители

By Trading Economics

Приходи

28M

-84M

Продажби

92M

593M

EPS

0.06

Марж на печалбата

-14.121

Служители

2,230

EBITDA

-92M

-155M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+26.42% upside

Дивиденти

By Dow Jones

Следващи печалби

1.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-46M

35B

Предишно отваряне

262.32

Предишно затваряне

267.08

Настроения в новините

By Acuity

50%

50%

180 / 386 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

Alnylam Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

12.09.2024 г., 17:01 ч. UTC

Топ новини

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- Update

12.09.2024 г., 11:00 ч. UTC

Топ новини

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ

Сравнение с други в отрасъла

Ценова промяна

Alnylam Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

26.42% нагоре

12-месечна прогноза

Среден 323.33 USD  26.42%

Висок 500 USD

Нисък 206 USD

Според 22 анализатори от Wall Street, предложили 12-месечна ценова цел за Alnylam Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

22 ratings

18

Купи

4

Задържане

0

Продай

Техническа оценка

By Trading Central

243.87 / 271.02Подкрепа & съпротива

Краткосрочен план

Bearish Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Weak Bearish Evidence

Настроение

By Acuity

180 / 386 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.